New Standard-of-Care Therapy for Advanced Liver Cancer
— Stereotactic body radiotherapy plus sorafenib improves survival versus targeted drug alone
by Charles Bankhead, Senior Editor, MedPage Today October 24, 2022
SAN ANTONIO -- Adding radiation therapy to systemic treatment significantly improved overall survival (OS) in advanced liver cancer, according to a randomized trial reported here.
Median OS improved from 12.3 months with the targeted drug sorafenib (Nexavar) to 15.8 months with stereotactic body radiation therapy (SBRT) followed by sorafenib. Landmark survival analyses from 6 to 24 months all favored the SBRT arm, and the magnitude of the benefit increased over time.
"In patients with advanced hepatocellular carcinoma, compared to sorafenib alone, SBRT prior to sorafenib improved overall survival, progression-free survival (PFS), and time to progression (TTP), without a concerning increase in adverse events," reported Laura Dawson, MD, of Princess Margaret Cancer Center in Toronto, at the American Society for Radiation Oncology (ASTRO) annual meeting.作者: StephenW 时间: 2022-10-25 11:20